Election Alters Ways & Means, Sparks Waxman Bid For Energy Panel Chair
This article was originally published in The Gray Sheet
Executive Summary
The Nov. 4 election that swept a new Democratic president and House and Senate candidates into office resulted in some shake-ups in congressional committees that handle medical device-related legislation
You may also be interested in...
Sens. Grassley, Kohl Retool Physician Payment Bill To Defuse Opposition
Senate lawmakers redrafted pending legislation that would require device and drug companies to publicly disclose financial relationships with doctors in response to steady lobbying by industry
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.